Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study
Go back to Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study| Roche Holding AG Basel American Depositary Shares (AMEX: RHHBY) | Delayed: 59.48 +0.37 (0.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $59.11 | 52 Week High | $35.13 | |||
| Open | $58.65 | 52 Week Low | $28.10 | |||
| Day High | $59.49 | P/E | N/A | |||
| Day Low | $58.41 | EPS | $0.00 | |||
| Volume | 516,945 | |||||



